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Objective. Systemic juvenile idiopathic arthritis (JIA) is characterized by fevers, rash, and arthritis, for which interleu-
kin-1 (IL-1) and IL-6 inhibitors appear to be effective treatments. Pulmonary arterial hypertension (PAH), interstitial lung
disease (ILD), and alveolar proteinosis (AP) have recently been reported with increased frequency in systemic JIA
patients. Our aim was to characterize and compare systemic JIA patients with these complications to a larger cohort of
systemic JIA patients.
Methods. Systemic JIA patients who developed PAH, ILD, and/or AP were identiﬁed through an electronic Listserv and
their demographic, systemic JIA, and pulmonary disease characteristics as well as their medication exposure information
were collected. Patients with these features were compared to a cohort of systemic JIA patients enrolled in the Childhood
Arthritis and Rheumatology Research Alliance (CARRA) registry.
Results. The patients (n  25) were signiﬁcantly (P < 0.05) more likely than the CARRA registry cohort (n  389) to be
female; have more systemic features; and have been exposed to an IL-1 inhibitor, tocilizumab, corticosteroids, intrave-
nous immunoglobulin, cyclosporine, and cyclophosphamide. Twenty patients (80%) were diagnosed with pulmonary
disease after 2004. Twenty patients (80%) had macrophage activation syndrome (MAS) during their disease course and
15 patients (60%) had MAS at pulmonary diagnosis. Sixteen patients had PAH, 5 had AP, and 7 had ILD. Seventeen
patients (68%) were taking or recently discontinued (<1 month) a biologic agent at pulmonary symptom onset; 12 patients
(48%) were taking anti–IL-1 therapy (primarily anakinra). Seventeen patients (68%) died at a mean of 10.2 months from
the diagnosis of pulmonary complications.
Conclusion. PAH, AP, and ILD are underrecognized complications of systemic JIA that are frequently fatal. These
complications may be the result of severe uncontrolled systemic disease activity and may be inﬂuenced by medication
exposure.
INTRODUCTION
Systemic juvenile idiopathic arthritis (JIA) is a distinct
category of JIA that is characterized as arthritis accompa-
nied by characteristic systemic features (mainly quotidian
fevers and evanescent rash, but often also organomegaly,
lymphadenopathy, and serositis). In addition to these fea-
tures, systemic JIA patients often have highly abnormal
acute-phase reactants, anemia, and hyperferritinemia. The
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(ILAR) criteria are most widely accepted for children un-
der the age of 16 years (1). Systemic JIA patients are sus-
ceptible to a potentially fatal complication called macro-
phage activation syndrome (MAS), which is characterized
by unremitting fever, pancytopenia, coagulopathy, and or-
gan dysfunction, commonly of the liver and central ner-
vous system (2–4). Tissue biopsies often show foamy mac-
rophages and active phagocytosis of blood elements
(hemophagocytosis). MAS is thought to be an acquired
form of hemophagocytic lymphohistiocytosis (2,3,5–7).
Many systemic JIA patients with active systemic features
are thought to have subclinical MAS (2–4,8). One study of
bone marrow biopsies of systemic JIA patients at disease
diagnosis showed the presence of hemophagocytosis even
when overt clinical features of MAS were absent (9).
In addition to increased morbidity and poorer functional
outcomes when compared with other forms of JIA (10,11),
systemic JIA patients have an increased risk of death, with
a mortality hazard ratio that can be almost double that of
other JIA categories mostly because of complications such
as MAS and serious infections (2,4,12). Recently, advances
in the understanding of systemic JIA and the discovery of
its excellent response to interleukin-1 (IL-1) and IL-6 in-
hibitors have resulted in an improved prognosis for many
patients with this difﬁcult-to-treat disease (13–19).
Nearly 4 years ago, spontaneous reports emerged about
an international pediatric rheumatology electronic List-
serv of unusual pulmonary complications in systemic JIA
patients that were often fatal, especially pulmonary arte-
rial hypertension (PAH) (20). Although pleuritis, along
with pericarditis, is a commonly recognized feature of
systemic JIA (11,21), other pulmonary complications, such
as PAH, interstitial lung disease (ILD), and alveolar pro-
teinosis (AP) or lipoid pneumonia, are extremely rare.
Prior to 2008, only scattered single case reports of PAH,
AP, ILD, and illnesses that may represent one of these
conditions in systemic JIA and Still’s disease existed in the
literature (22–27), so the number of cases being reported to
the Listserv represented an increase. Because IL-1 inhibi-
tors became much more commonly used in systemic JIA in
the mid-2000s, there was concern about a possible associ-
ation between exposure to biologic medications such as
IL-1 inhibitors and the development of pulmonary com-
plications in some patients (16,17). In this study, we
sought to identify and describe systemic JIA patients with
these pulmonary complications and analyze the disease
features that might identify characteristics speciﬁc to these
patients.
PATIENTS AND METHODS
A retrospective chart review of patients with systemic JIA
who developed PAH, ILD, and/or AP was performed.
Cases were solicited initially in 2008 and then again in
May 2011 through an international pediatric rheumatology
electronic Listserv managed by McMaster University (On-
tario). Approval was obtained from the Hackensack Uni-
versity Medical Center Institutional Review Board to col-
lect deidentiﬁed data for analysis. A questionnaire was
designed to collect information on demographics, disease
characteristics, medication usage, pulmonary disease
symptoms, diagnosis and treatment, and laboratory and
other diagnostic data. The disease and demographic char-
acteristics and medication history of the study cohort were
compared to baseline data of a cross-sectional cohort of
systemic JIA patients enrolled in the Childhood Arthritis
and Rheumatology Research Alliance (CARRA) pediatric
rheumatic diseases registry. Statistical analysis was per-
formed using frequencies and the data set variables were
compared using Fisher’s exact test to determine a P value.
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Signiﬁcance & Innovations
● Serious pulmonary complications are being re-
ported with increased frequency and are fre-
quently fatal in systemic juvenile idiopathic ar-
thritis (JIA) patients.
● The characteristics of these pulmonary complica-
tions, disease features, and medication exposures
in the affected patients need to be studied.
● This study used systemic JIA patients enrolled in
the Childhood Arthritis and Rheumatology Re-
search Alliance registry as a comparator group,
which is the largest known database of JIA patients
in the world.
● The affected patients had increased severity of sys-
temic disease and more exposure to medications,
especially biologic agents.
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RESULTS
Demographic and disease characteristics. Twenty-ﬁve
cases were identiﬁed from the US (n  19), Spain (n  1),
the UK (n  1), The Netherlands (n  1), Italy (n  1), and
Brazil (n  2). Twenty-four of the subjects met the ILAR
criteria for systemic JIA. The 1 remaining patient met the
ILAR criteria, except that she was 17 years old when her
systemic JIA symptoms began. The CARRA registry cohort
consisted of 389 patients at the time of the data cut (April
30, 2012). Table 1 shows the disease and demographic
characteristics of the 2 cohorts. Although age at diagnosis,
race/ethnicity, and common disease features were similar
between the 2 cohorts, the study cohort had a signiﬁcantly
larger proportion of female patients and patients with
lymphadenopathy and organomegaly (splenomegaly
and/or hepatomegaly). Disease or treatment complications
in the study cohort included growth failure (40%), osteo-
porosis (40%), pathologic fractures (8%), cataracts (24%),
avascular necrosis (12%), and amyloidosis (4%). Twenty
patients (80%) had at least 1 episode of MAS and 16
patients (64%) had a serious infection (including sepsis,
salmonella gastroenteritis, adenovirus gastroenteritis,
pneumonia, Clostridium difﬁcile enteritis, typhlitis, and
ascariasis) during the course of their disease. Other com-
plications included psychosis (1 patient), myositis (1 pa-
tient), transient ischemic attack (1 patient), thrombotic
thrombocytopenia purpura (1 patient), and dyslipidemia
(1 patient). There were signiﬁcant differences in the de-
cade of disease onset between the 2 cohorts, with more
patients in the CARRA registry (87%) having onset after
2000 compared to the study cohort (76%).
Medication exposures. Medications that the study co-
hort had ever taken were compared to those of the CARRA
registry cohort (Table 2). Signiﬁcant differences were
found, with the study cohort having more exposure to any
IL-1 inhibitor (also speciﬁcally to anakinra and canaki-
numab), tocilizumab, intravenous immunoglobulin (IVIG),
high-dose methylprednisolone pulse treatments, cyclo-
phosphamide, and cyclosporine.
Pulmonary disease features. The pulmonary disease
features in the study cohort are shown in Table 3. Dyspnea
on exertion and shortness of breath were the most common
symptoms; the other symptoms included clubbing, cough,
and chest pain. Two patients had shortness of breath as
their only symptom and 3 patients had only clubbing. One
patient was diagnosed at autopsy and did not have any
known prior pulmonary symptoms. Twenty-four patients
(96%) developed pulmonary disease after 2000, and 20
patients (80%) developed pulmonary disease after 2004.
Sixteen patients (64%) had PAH, 5 patients (20%) had AP
and/or lipoid pneumonia, and 7 patients (28%) had ILD.
Six patients had 1 diagnosis; 2 patients had PAH and
ILD, 2 patients had PAH and AP, and 2 patients had AP
and ILD. There were no clinical features that distinguished
the speciﬁc pulmonary diagnoses. The following diagnos-
Table 1. Patient demographics and systemic JIA disease characteristics*
Study cohort
(n  25)
CARRA registry
cohort (n  389)† P
Age at systemic JIA diagnosis, mean  SD
(range) years
7.4  5.5 (1.1–17.2) 5.8  4.3 (0.2–15.9) NS
Disease duration, mean  SD (range) months 51.6  48.8 (8–173)‡ 61.9  51 (0.6–219.5) 0.012
Female 19 (76) 213 (55) 0.040
Race NS
White 17 (68) 302 (78)
African American 7 (28) 45 (12)
Asian 1 (4) 20 (5)
Other/unknown 0 (0) 20 (5)
Ethnicity NS
Hispanic 5 (20) 50 (13)
Non-Hispanic 20 (80) 337 (87)
JIA symptoms (ever had during disease course)
Fever 25 (100) 352 (93) NS
Rash 23 (92) 326 (87) NS
Arthritis 25 (100) 378 (100) NS
Lymphadenopathy 19 (76) 157 (46)  0.001
Hepatomegaly or splenomegaly 20 (80) 102 (31)  0.001
Serositis 14 (56) Unknown N/A
Decade of disease onset 0.0068
1980s 1 (4) 0
1990s 5 (20) 35 (9)
2000 and later 19 (76) 335 (87)
Unknown 0 16 (4)
* Values are the number (percentage) unless otherwise indicated. JIA  juvenile idiopathic arthritis; CARRA  Childhood
Arthritis and Rheumatology Research Alliance; NS  not signiﬁcant (P  0.05); N/A  not applicable.
† Sum of all frequencies may not be equal to the total sample size because of missing values.
‡ At the time of pulmonary complication diagnosis.
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tic tests were performed: electrocardiogram (8 of 19 abnor-
mal), chest radiographs (15 of 21 abnormal), echocardio-
gram (18 of 24 abnormal), chest computed tomography
scan (18 of 20 abnormal), pulmonary function tests (13 of
13 abnormal), cardiac catheterization (9 of 10 abnormal),
and lung biopsy (11 of 12 abnormal). Seventeen patients
(68%) died within a mean  SD time of 10.2  13 months
from the diagnosis of their pulmonary disease. Seven of
these patients also had a serious infection near the time of
death. The remaining 8 patients survived for a mean  SD
time of 56.2  35.3 months (range 16–106 months) from
the time of pulmonary disease diagnosis (as of June 15,
2012).
Concomitant features of systemic JIA. Twenty-three
patients (92%) had systemic features at the time of pulmo-
nary disease diagnosis (Table 3), including fever (15 pa-
tients), rash (7 patients), serositis (6 patients), lymphade-
nopathy (6 patients), hepatomegaly (11 patients), and
splenomegaly (12 patients). One patient had thrombotic
thrombocytopenic purpura. Fifteen patients (60%) had
MAS (suspected or conﬁrmed) at the time of the pulmo-
nary disease diagnosis. All 15 patients fulﬁlled the Ravelli
preliminary criteria for MAS (28). Five of these patients
also had tissue conﬁrmation of MAS; 2 patients had he-
mophagocytosis on bone marrow biopsy, 1 on lung biopsy,
1 on myocardial biopsy, and 1 patient had iron-laden
macrophages in the bronchoalveolar lavage ﬂuid. A six-
teenth patient who did not fulﬁll the Ravelli criteria at the
time of diagnosis had a rapidly deteriorating course and
died 5 months later; the autopsy showed multiple organs
with evidence of hemophagocytosis.
Medication exposures at onset of pulmonary symptoms.
Seventeen patients (68%) had been exposed to1 biologic
disease-modifying antirheumatic drug (DMARD) at the on-
set of pulmonary symptoms (Table 4). An IL-1 inhibitor
(primarily anakinra) was the most common biologic
DMARD taken, with 12 patients (48%) either taking an
IL-1 inhibitor or having recently (1 month) discontinued
it at the time their pulmonary symptoms developed (n 
3). The other biologic DMARDs included tumor necrosis
factor (TNF) inhibitors (12%) and tocilizumab (8%).
Twenty-one patients (84%) were taking 1 medications at
the time of symptom onset and 13 were taking combina-
tions of DMARDs. Three patients had been exposed to a
combination of biologic DMARDs within a month of symp-
tom onset; 1 was taking a combination of TNF and IL-1
inhibitors and 2 had been exposed to an IL-1 and IL-6
inhibitor within 1 month of the other. However, there was
Table 2. Medications used during disease course*
Study cohort
(n  25)
CARRA registry
cohort (n  389) P
Biologic DMARDs
Abatacept 2 (8) 19 (6) NS
IL-1 inhibitor (any) 20 (80) 168 (43)  0.001
Anakinra 20 (80) 156 (40)  0.001
Canakinumab 3 (12) 7 (2) 0.018
Rilonacept 4 (16) 27 (7) NS
IVIG 7 (28) 24 (6) 0.001
Rituximab 0 (0) 7 (2) NS
Tocilizumab 5 (20) 29 (8) 0.044
TNF inhibitor (any) 15 (60) 174 (45) NS
Adalimumab 5 (20) 48 (12) NS
Certolizumab 0 (0) 2 (1) NS
Etanercept 12 (48) 140 (36) NS
Golimumab 0 (0) 2 (1) NS
Inﬂiximab 6 (24) 54 (14) NS
Glucocorticoids
Methylprednisolone pulses 23 (92) 122 (31)  0.001
Prednisone 25 (100) 336 (86) NS
Nonbiologic DMARDs NR
Mycophenolate mofetil 3 (12) 12 (3) NS
Cyclophosphamide 5 (20) 7 (2) 0.001
Cyclosporine 14 (56) 45 (12)  0.001
Etoposide 5 (20) NR
Gold 1 (4) NR
Methotrexate 22 (88) 232 (78) NS
Penicillamine 1 (4) NR
Tacrolimus 2 (8) 8 (2) NS
Thalidomide 4 (16) NR
* Values are the number (percentage). CARRA  Childhood Arthritis and Rheumatology Research
Alliance; DMARD  disease-modifying antirheumatic drug; NS  not signiﬁcant (P  0.05); IL-1 
interleukin-1; IVIG  intravenous immunoglobulin; TNF  tumor necrosis factor; NR  not reported.
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no consistent pattern of medication combination expo-
sures among the patients.
DISCUSSION
Although isolated case reports of PAH, AP, and ILD in
systemic JIA and adult-onset Still’s disease have been pub-
lished (22–27,29,30), the ﬁndings in this study indicate
that these complications may occur more commonly than
previously suspected and are fatal in the majority of pa-
tients. PAH, ILD, and AP are all processes in which in-
ﬂammation likely has an important role; for example,
pathologic PAH specimens show an increased inﬂamma-
tory perivascular inﬁltrate, including macrophages, den-
dritic cells, lymphocytes, and mast cells (31–33). In AP,
there is an accumulation of lipoproteinaceous material in
the airways due to macrophage dysfunction and ineffec-
tive clearance in the alveoli as well as the presence of
foamy macrophages (29,34). AP can coexist with lipoid
pneumonia, in which cholesterol clefts and an inﬂamma-
tory inﬁltrate can be seen. In addition, C-reactive protein
levels have been shown to be increased in patients with
PAH and correlated with the severity of disease (35). In-
fections, toxins, and drugs have long been hypothesized as
having a primary or secondary role in triggering PAH.
Increased levels of cytokines, especially IL-1, IL-6, and
TNF, have been found in the serum and tissue of patients
with PAH (36–38). In addition, hereditary PAH and a
minority of sporadic PAH cases are associated with
heterozygous mutations in bone morphogenetic protein
receptor type II (BMPRII); reduced expression of BMPRII is
associated with endothelial cell dysfunction and the de-
velopment of PAH (39–41). IL-6, which is increased in
systemic JIA patients with active systemic features (42–
44), decreases the expression of BMPRII in vitro. There-
fore, increased IL-6 levels characteristic of active systemic
Table 3. Clinical features at pulmonary disease diagnosis (n  25)*
Value
Age at start of pulmonary symptoms, mean  SD
(range) years
11.7  5.2 (3.5–18.8)
Disease duration at pulmonary diagnosis, mean  SD
(range) months
50.6  44.6 (8–160)
Time between pulmonary symptoms to diagnosis,
mean  SD (range) months
3.1  3.2 (0–10)
Time between pulmonary diagnosis to death (n  17),
mean  SD (range) months
10.2  13 (0–44)
Disease features at pulmonary disease diagnosis
Systemic JIA manifestations
Any systemic manifestation† 23 (92)
MAS (suspected or conﬁrmed) 15 (60)
Pericarditis or serositis 11 (44)
Thrombotic thrombocytopenic purpura 1 (4)
Arthritis 16 (64)
Pulmonary symptoms
Shortness of breath 16 (64)
Dyspnea on exertion 18 (72)
Cough 11 (44)
Clubbing 10 (40)
Chest pain 5 (20)
Pulmonary diagnosis
Pulmonary arterial hypertension 16 (64)
Alveolar proteinosis 5 (20)
Interstitial lung disease 7 (28)
* Values are the number (percentage) unless otherwise indicated. JIA  juvenile idiopathic arthritis;
MAS  macrophage activation syndrome.
† Includes patients with one or more of the following: fever, rash, lymphadenopathy, hepatomegaly, and
splenomegaly.
Table 4. Medications being taken at the time of
development of pulmonary symptoms or discontinued
within a month prior to symptoms*
Medication
No.
patients Exposure, months
Corticosteroids 24 47.3  48.2 (3–161)
Cyclosporine 7 6.3  7.3 (1–22)
Etoposide 1 1
Gold 1 53
Methotrexate 13 32.9  38.2 (1–126)
Thalidomide 1 22
IL-1 inhibitor (any) 12 15.1  15.0 (3–47)
Anakinra 10 16.9  15.9 (3–47)
Canakinumab 1 6
Rilonacept 1 6
TNF inhibitor (any) 3 17.0  13.1 (2–26)
Adalimumab 2 12.5  14.9 (2–23)
Etanercept 1 26
Tocilizumab 2 6.0  7.1 (1–11)
* Values are the mean  SD (range). IL-1  interleukin-1; TNF 
tumor necrosis factor.
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JIA may contribute to the development of PAH in these
individuals.
Of interest is the fact that 96% of the patients developed
these pulmonary complications after 2000 (and 80% after
2004) because biologic DMARDs (especially IL-1 inhibi-
tors) became much more commonly used for systemic JIA
in the mid-2000s. Of all the patients, 68% were taking a
biologic DMARD (most commonly an IL-1 inhibitor) at the
time of the development of pulmonary symptoms and had
an increased likelihood of ever being exposed to biologic
agents, especially IL-1 inhibitors, compared to the CARRA
registry cohort. When the decade of disease onset was
examined, the study cohort was signiﬁcantly less likely to
have been diagnosed after the year 2000 compared to the
CARRA registry cohort, making it unlikely that the reason
for the increased exposure to biologic agents in the study
cohort was simply due to these patients having been diag-
nosed more recently. These facts raise the concern of a
possible causal relationship between exposure to these
medications and the development of pulmonary compli-
cations.
Although the biologic agent most frequently taken by the
study cohort was anakinra, which was taken by 80% of the
study patients compared to 40% of the CARRA registry
cohort (P  0.001), other biologic agents with signiﬁcantly
increased exposure included canakinumab, tocilizumab,
and IVIG (Table 2). Of note, the patient who developed
PAH while taking canakinumab had also been exposed to
tocilizumab (which was discontinued 4 months prior to
the onset of pulmonary symptoms) and 2 additional pa-
tients who developed PAH were also taking tocilizumab.
An additional patient not included in the study cohort
who developed AP while taking tocilizumab was recently
included in the pediatric rheumatology Listserv. Tocili-
zumab has been used much more frequently since it was
approved for use in systemic JIA by the US Food and Drug
Administration and the European Medicines Agency in
2011; therefore, the incidence of pulmonary events should
be closely monitored through systematic postmarketing
studies. A similar surveillance of patients exposed to ca-
nakinumab should also be conducted because this drug is
also likely to receive a similar indication by regulatory
agencies. Anakinra is currently the most commonly used
biologic agent for systemic JIA even though it has not been
speciﬁcally studied in this population and does not have a
postmarketing commitment or requirement. However, the
majority of the patients in the study cohort were exposed
to this medication, underlining the importance of perform-
ing systematic prospective monitoring of all systemic JIA
patients whether or not there is a postmarketing require-
ment of a speciﬁc medication.
It is also clear that most of the study patients had severe
systemic diseases that likely resulted in increased medi-
cation exposures when compared with the CARRA registry
cohort, including IV pulse corticosteroids, cyclophos-
phamide, and cyclosporine as well as biologic DMARDs.
Many of these patients had active systemic features (in-
cluding MAS) at the time of the pulmonary disease diag-
nosis; thus, it seems likely that systemic inﬂammatory
disease severity played an important role in the pathogen-
esis of PAH, ILD, and AP. In fact, 2 of the patients had
evidence of hemophagocytosis in non–bone marrow tissue
specimens (lung and myocardium). Disease severity itself
is therefore likely to play an important role in the patho-
genesis of these pulmonary complications; systemic fea-
tures in the study cohort appeared to be signiﬁcantly
increased compared to the CARRA registry cohort, specif-
ically hepatosplenomegaly and lymphadenopathy (both
P  0.001) (Table 1). The frequencies of serositis (56%)
and MAS (80%), both markers of systemic disease sever-
ity, were also much higher than expected in the study
cohort, although an adequate comparison was not possible
because the frequencies of these features were not col-
lected in the CARRA registry population. Both IL-1 inhib-
itors (13,14,17,19,45–47) and anti–IL-6 antibodies (tocili-
zumab) have been found to be highly effective in systemic
JIA (15,48,49). It remains to be seen whether effective
treatments, including IL-1 and IL-6 inhibition, will reduce
the incidence of pulmonary complications in patients with
systemic JIA rather than being a possible causative factor.
It will be important to understand the epidemiology and
pathophysiology of adverse events such as PAH, AP, and
ILD, and their relationship to medication exposure as well
as disease severity, because while biologic DMARDs are
being used with increased frequency, systemic JIA itself is
associated with signiﬁcantly increased morbidity and mor-
tality compared to other categories of JIA (10–12,21) and
because biologic DMARDs are now being used with in-
creased frequency (50). Traditional single-product phase
IV registries will not be useful for understanding whether
speciﬁc medication exposures lead to these adverse events
because PAH, AP, and ILD are rare occurrences in a rare
disease like systemic JIA. A consolidated disease registry
in which all patients with systemic JIA are enrolled regard-
less of medication exposure would be the ideal vehicle to
capture such information (51). This registry would have
the advantage of being able to prospectively identify and
follow a large cohort of systemic JIA patients taking differ-
ent medications over extended periods of time. In this
way, the frequency of pulmonary complications in pa-
tients with systemic JIA and their association with speciﬁc
medication exposures could be captured and analyzed
efﬁciently and accurately, while taking into account con-
founders such as disease severity.
The limitations of this study include its retrospective
design and possible reporting and recall bias. There is a
recent heightened awareness of pulmonary complications
in patients with systemic JIA as well as an improved
ability to diagnose them. Despite this study being the
largest reported cohort of patients with these severe pul-
monary complications, there were not enough patients
with each pulmonary diagnosis to be able to discern dif-
ferences in clinical presentation. Last, the comparator
CARRA registry cohort data are from a cross-sectional
convenience sample of systemic JIA patients followed at
the 52 CARRA registry sites. The registry is one of the
largest contemporary cohorts of JIA patients currently
available but may not reﬂect an accurate sampling of typ-
ical systemic JIA patients.
Despite recent advances in therapy, systemic JIA re-
mains a disease with signiﬁcant morbidity and mortality.
This study marks the ﬁrst time that a large cohort of sys-
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temic JIA patients who developed PAH, AP, and ILD has
been described. PAH, AP, and ILD are important but un-
derrecognized complications of systemic JIA that are likely
to be the result of severe uncontrolled systemic disease
activity and inﬂammation but may be inﬂuenced by expo-
sure to certain medications. Further prospective studies
are needed to determine the factors associated with the
development of these pulmonary complications. Increased
awareness regarding these pulmonary complications in
systemic JIA is needed and screening for these complica-
tions should be considered in systemic JIA patients with
signiﬁcant and persistent systemic disease activity.
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